Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Recurrence × Anastrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 66 Neoplasms 7 Breast Neoplasms, Male 4 Neoplasm Metastasis 3 Carcinoma, Intraductal, Noninfiltrating 3 Arthralgia 3 Triple Negative Breast Neoplasms 2 Sexual Dysfunction, Physiological 1 Seizures 1 Recurrence 1 Pain 1 Osteoporosis 1 Obesity 1 Multiple Endocrine Neoplasia Type 1 1 Lethal Congenital Contracture Syndrome 2 1 Joint Diseases 1 Invasive Breast Cancer 1 Hypogonadism 1 Granulosa Cell Ovarian Cancer 1 Fractures, Bone 1 Erectile Dysfunction 1 Epilepsy 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Advanced Metastatic Breast Cancer 1 Advanced Breast Carcinoma 1

Interventions

Cyclophosphamide 31 Dexamethasone 29 Cytarabine 21 Rituximab 20 fludarabine phosphate 19 Lenalidomide 17 Methotrexate 16 fludarabine 15 Bortezomib 15 Calcium Dobesilate 14 Whole-Body Irradiation 13 Etoposide 13 pembrolizumab 12 Peripheral Blood Stem Cell Transplantation 12 Mycophenolic Acid 12 Melphalan 12 Paclitaxel 11 Gemcitabine 11 Filgrastim 11 Cyclosporine 11 Carboplatin 11 pomalidomide 9 Busulfan 9 carfilzomib 8 Vincristine 8 Panobinostat 8 Clofarabine 8 Cetuximab 8 Brentuximab Vedotin 8 Bevacizumab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00256698 2012-08-01

FACT

AstraZeneca

Phase 3 Completed

514 enrolled 13 charts

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡